Neuphoria Therapeutics (NEUP) Shares Outstanding (Diluted Average) (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Shares Outstanding (Diluted Average) of $4.1 million for Q1 2026, up 165.25% year-over-year from $1.5 million in Q1 2025, and down 10.53% on a QoQ basis from $4.5 million in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Shares Outstanding (Diluted Average) data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Shares Outstanding (Diluted Average) rose 165.25% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 165.25% YoY) and the FY2025 annual result came in at $1.6 million, up 95.01% from the prior year.
- Shares Outstanding (Diluted Average) fell to $4.1 million in Q1 2026 per NEUP's latest filing, from $4.5 million in the prior quarter.
- Across five years, Shares Outstanding (Diluted Average) topped out at $1.5 billion in Q3 2023 and bottomed at $832225.0 in Q2 2024.
- The 4-year median for Shares Outstanding (Diluted Average) is $1.6 million (2025), against an average of $208.1 million.
- The widest annual swing landed in 2024, when Shares Outstanding (Diluted Average) tumbled 99.92%; it then soared 215.53% in 2025.
- Tracing NEUP's Shares Outstanding (Diluted Average) over 4 years: stood at $857264.0 in 2023, then jumped by 67.7% to $1.4 million in 2024, then soared by 215.53% to $4.5 million in 2025, then slipped by 10.53% to $4.1 million in 2026.
- Per Business Quant, the three latest NEUP Shares Outstanding (Diluted Average) figures stand at $4.1 million (Q1 2026), $4.5 million (Q4 2025), and $2.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 4.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | 4.54 Mn |
| Sep 30, 2025 | 2.25 Mn |
| Jun 30, 2025 | 1.62 Mn |
| Mar 31, 2025 | 1.53 Mn |
| Dec 31, 2024 | 1.44 Mn |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 832,225.00 |
| Mar 31, 2024 | 842,431.00 |
| Dec 31, 2023 | 773,976.00 |
| Sep 30, 2023 | 1.50 Bn |
| Jun 30, 2023 | 981.64 Mn |